About this resource:

HHS Non-systematic Review

Source: Food and Drug Administration, 2003

Last Reviewed: August 2018

Workgroups: Food Safety Workgroup

Read more about this resource

Objectives related to this resource (2)

Prevent an increase in the proportion of nontyphoidal Salmonella infections that are resistant to multiple drug classes — FS‑05
Baseline only
Prevent an increase in the proportion of macrolide antibiotic-resistant Campylobacter infections — FS‑06
Baseline only

Suggested Citation

1.

Center for Veterinary Medicine, U.S. Food and Drug Administration. (2003). CVM GFI #152 evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects